Kendrick Lamar’s major-label debut album good kid m.A.A.d. city, released in October 2012, provides rich narratives relating to important mental health themes, including addiction, depression and stress resilience, according to the co-founders of HIP HOP PSYCH, a new initiative to tackle mental health issues through hip-hop.
Researchers have identified how proteins that play a key role in Alzheimer’s disease are linked in a pathway that controls its progression, and that drugs targeting this pathway may be a potential new way of treating the disease.
“Listen to your heart,” sang Swedish pop group Roxette in the late Eighties. But not everyone is able to tune into their heartbeat, according to an international team of researchers – and half of us under- or over-estimate our ability.
New funding will support fundamental research into the molecular processes underlying human disorders such as Alzheimer’s and Parkinson’s diseases, and enable new ways to combat them.
A survey of almost 400,000 British residents has highlighted significant differences in personalities between regions. Amongst its findings, it shows Scots to be amongst the friendliest and most co-operative residents, Londoners the most open and Welsh people the least emotionally stable.
Intentionally recalling memories may lead us to forget other competing experiences that interfere with retrieval, according to a study published today. In other words, the very act of remembering may be one of the major reasons why we forget.
A molecular chaperone has been found to inhibit a key stage in the development of Alzheimer’s disease and break the toxic chain reaction that leads to the death of brain cells, a new study shows. The research provides an effective basis for searching for candidate molecules that could be used to treat the condition.
Alzheimer’s Research UK, the world’s largest dedicated dementia research charity, has announced a £30 million Drug Discovery Alliance, launching three flagship Drug Discovery Institutes at the Universities of Cambridge, Oxford and UCL (University College London). The Drug Discovery Institutes will see 90 new research scientists employed in state-of-the-art facilities to fast-track the development of new treatments for Alzheimer’s disease and other dementias.